Traditional Chinese medicine active monomer component with liver protection function and uses thereof

A technology of uses and drugs, applied in the field of pharmacy, can solve the problems of insufficient organ source, aggravated osteoporosis, and high cost.

Inactive Publication Date: 2008-12-03
SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI +1
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, for liver cirrhosis caused by viral hepatitis, there is currently no sure and effective drug for reversing liver cirrhosis, and some traditional Chinese medicines for promoting blood circulation and resolving stasis and softness can be used for anti-fibrosis treatment of early liver cirrhosis
In the treatment of alcoholic hepatitis and autoimmune hepatitis, immunosuppressants represented by adrenal cortex hormon

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Traditional Chinese medicine active monomer component with liver protection function and uses thereof
  • Traditional Chinese medicine active monomer component with liver protection function and uses thereof
  • Traditional Chinese medicine active monomer component with liver protection function and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0026] According to one embodiment of the present invention, Tanshinone IIA can be administered to a subject in need of treatment to treat or prevent liver damage. In a preferred embodiment, the liver injury is immune-mediated liver injury. Immune-mediated liver injury is a general term for all immune-mediated liver injuries, and plays an important role in the pathogenesis of many hepatitis. Immune-mediated liver injury includes, but is not limited to: viral hepatitis, alcoholic hepatitis, autoimmune hepatitis and other liver injury diseases. Liver injury, liver fibrosis, and liver cancer are different pathological stages of liver injury. Immune-mediated liver injury generally occurs in the acute phase or the early chronic phase. If it changes from the acute phase to the chronic phase, it will lead to liver fibrosis. If the self-repair system of liver cells is disordered, a large number of malignant proliferation of cells will turn into liver cancer.

[0027] According to an...

Embodiment 1

[0047] Example 1: Tanshinone IIA reduces alanine aminotransferase activity in serum of CIH mice

[0048] test subject

[0049] Male C57BL / 6 mice, 8-10 weeks old, were purchased from Shanghai SLAC Experimental Animal Co., Ltd. Randomly divided into groups, the control group, the low concentration administration group (5mg / kg), and the high concentration administration group (10mg / kg) each have 4-5 rats.

[0050] Experimental procedure

[0051] Mice were given phosphate-buffered saline (PBS, control group) or tanshinone IIA (test group) by intraperitoneal injection, the doses were 5 mg / kg body weight or 10 mg / kg body weight respectively, that is, sodium tanshinone IIA sulfonate was dissolved in PBS, and in mice The final concentrations were 5mg / kg and 10mg / kg body weight respectively. Four hours later, all mice received the same administration treatment, and then all mice were injected with ConA at a dose of 15 mg / kg body weight in the tail vein. After 17 hours, the serum ...

Embodiment 2

[0055] Example 2: Tanshinone IIA significantly reduces liver inflammatory infiltration and necrosis in CIH model mice

[0056] test subject

[0057] Male C57BL / 6 mice, 8-10 weeks old, were purchased from Shanghai SLAC Experimental Animal Co., Ltd. Randomly divided into groups, 4-5 each in the control group and the administration group (5mg / kg).

[0058] Experimental procedure

[0059] Mice were given PBS (control group) or Tanshinone II A (test group) at a dose of 5 mg / kg by intraperitoneal injection. Four hours later, the same administration treatment was performed. Subsequently, all mice were injected with ConA at a dose of 15 mg / kg through the tail vein. Eight hours later, liver tissue sections were taken for H&E staining or TUNEL staining. H&E staining or TUNEL staining methods were as described in the literature (Wang Y, Mei Y, Feng D, Xu L. Clin Exp Immunol. 2006 Sep; 145(3): 485-92). The kit used was purchased from Roche Molecular Biochemicals, Indianapolis, USA...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of tanshinone II A, namely natural extract of radix salviae miltiorrhizae, in preparation of medicines used for treating or preventing the liver damage. The invention also relates to an application of the tanshinone II A in preparation of medicines used for treating or preventing diseases related to the activity increase of glutamic pyruvic transaminase.

Description

technical field [0001] The present invention relates to the field of pharmacy. Specifically, the present invention relates to the protective effect of tanshinone II A, an active ingredient derived from traditional Chinese medicine, on liver damage. Background technique [0002] Hepatitis is a major disease that seriously endangers human health. The incidence of hepatitis, especially viral hepatitis, in China continues to be relatively high. As far as hepatitis B is concerned, 2 billion people in the world are infected with hepatitis B virus, of which 690 million are in China. There are carriers of hepatitis B virus surface antigen (HBsAg) around the world 350 million people, one-third of which are in China; 750,000 people in the world die every year from diseases caused by hepatitis B virus infection, of which 280,000 are from China. From the perspective of etiology, hepatitis mainly includes viral hepatitis, alcoholic hepatitis, and autoimmune hepatitis. However, studies...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/343A61K9/20A61K9/14A61K9/16A61K9/08A61K9/10A61K9/48A61K9/02A61K9/06A61K31/704A61K31/357A61P1/16A61P1/18A61P5/14A61P9/10A61P9/04
Inventor 徐凌云许艳冯德春
Owner SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap